As of Aug 16
| -0.05 / -1.59%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 18.00, with a high estimate of 26.00 and a low estimate of 10.00. The median estimate represents a +480.65% increase from the last price of 3.10.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.